Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs

March 1, 2017

March 01, 2017

A new report reveals the orphan drug market has grown at approximately double the overall growth of the prescription market. 

Highlights of the EvaluatePharma Orphan Drug Report 2017 include

  • Worldwide orphan drug sales forecast to total $209bn (CAGR 2017 to 2022:+11.1%)

  • Orphan drugs set to be 21.4% of worldwide prescription sales by 2022 (excluding generics)

  • Median cost per patient 5.5 times higher for orphan drugs compared to non-orphan

  • Celgene set to climb to number one position in orphan drug sales to 2022

  • Shire to be largest company by sales in the orphan non-oncology space in 2022

  • AstraZeneca, Abbvie and Johnson & Johnson set to march up the orphan drug sales ranking table

  • Revlimid (lenalidomide) No.1 orphan drug in 2022

  • Opdivo (nivolumab) No.1 orphan drug in Europe in 2022

  • Orphan drugs forecast to account for 55% of the cumulative value of the European pipeline to 2022

  • Axicabtagene Ciloleucel (Kite Pharma) is most valuable R&D orphan drug

  •  First decline since 2012 for FDA orphan designations in 2016 with 333; Record number of applications made to the FDA for orphan designation in 2016

The “EvaluatePharma Orphan Drug Report 2017” can be downloaded at: www.evaluategroup.com/orphandrug2017.